Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease. - Tsurutani J; Nozawa K; Mukohara T; Taira T; Yoshimura A; Nagai SE; Hashimoto J; Matsuura K; Mizuno T; Shinden Y; Yamamoto M; Takano T; et al. (Breast (Edinburgh, Scotland), 2026)